Immunoassay Analyzers Market Overview, Future Trends, Growth, Key Factors, Manufacture Players, Opportunities Analysis by 2032

Immunoassay Analyzers Market Scenario

Immunoassay analyzers is a device which measures the presence and concentration of proteins in analyte samples. These instruments are mostly used by pharmaceutical & biotechnological companies, laboratories, and research institutes. The global immunoassay analyzers market is driven by an increasing number of pharmaceutical and biotechnological companies, rising prevalence of different life-threatening diseases, and government’s initiatives for research & development activities. Furthermore, rapid development in diagnostic medical devices, increasing need for better drug treatment, and the increasing geriatric population had also fuelled the market’s growth. On the other hand, high cost of instruments and poor reimbursement policies may restrain this growth during the forecasted period. 

The Immunoassay Analyzers Market size was valued at USD 1.1 billion in 2022. The Immunoassay Analyzers market is projected to grow from USD1.1594 Billion in 2023 to USD 1.765867 billion by 2032, exhibitinga compound annual growth rate (CAGR) of 5.40% during the forecast period (2023 - 2032).

Regional Analysis

The global immunoassay analyzer market outlook is dominated by America, which is followed by Europe. Presence of huge diabetic and cancer population, large geriatric population, and well-developed healthcare sector has driven this market’s growth in America.   Europe immunoassay analyzer market is majorly driven by the presence of large number of pharmaceutical and biotechnological companies. Along with these, Asia Pacific also has the fastest growing immunoassay analyzer market due to rapidly developing economies with huge population base, mainly in India and China. However, the Middle East & Africa has the least market due to limited development in the healthcare sector. 

Increasing prevalence of different types of chronic diseases is fueling the growth of this market. The global immunoassay analyzer market is a highly competitive market due to the presence of many small and medium companies. These companies are focusing on the development of new and advances devices, while some companies have adopted strategies of acquisitions and strategic alliances, this will consequently lead to this market’s growth.
Hoffmann-La Roche Ltd, a Swiss multinational healthcare company, operates under two division, which are diagnostics and pharmaceuticals. In 2016, the company launched the new cobas e 801 modules, which will help hospitals and laboratories to meet the demand of diagnostic testing. Cobas e 602 is one of the most widely used devices of this company. 

Beckman Coulter, Inc., headquartered in California, US, is a manufacturer of biomedical laboratory instruments. In 2015, the company completed the acquisition of MicroScan from Siemens Healthcare. UniCel DxI 800, UniCel DxI 600, and Access 2 are some of the major immunoassay analyzer manufactured by this company. 

Market Players

Some of the major key players of this market are F. Hoffmann-La Roche Ltd.  (Switzerland), Siemens Ltd. (Germany), Abbott (US), Beckman Coulter, Inc. (US), Ortho Clinical Diagnostics (US), bioMérieux Private Limited (France), Biokit S.A (Spain), The Binding Site Group Ltd. (UK), Immunodiagnostic Systems (UK), Merck KGaA (US), Olympus Corporation (Japan), Nova Century Scientific, Inc. (US), Thermo Fisher Scientific (US), DiaSorin S.p.A. (Italy), and Randox Laboratories Ltd. (UK) 

Segmentation

The global immunoassay analyzer market is segmented on the basis of instruments, applications, and end users. On the basis of instruments, the market is classified into immunofluorescence, chemiluminescence, ELISA, enzyme linked fluorescent system, multiplexed assay system, radioimmunoassay and others. On the basis of application, the market is segmented into infectious diseases, autoimmune diseases, AIDS, endocrinology, drug monitoring, cardiology, oncology, allergy testing and others. On the basis of end users, the market is categorized into hospitals, diagnostic laboratories, research institutes, and others. 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Exploring the Transformative Potential of mixed reality in healthcare market

The mixed reality in healthcare market is expected to register a CAGR of 25.04% during the forecast period of 2022 to 2030, with an estimated market value of USD 9722.85 million in 2030. The field of healthcare is constantly evolving, driven by technological advancements that seek to improve patient care, enhance medical training, and streamline clinical workflows. One such innovation making significant waves in the industry is Mixed Reality (MR). Mixed Reality combines elements of the physical and virtual worlds to create immersive and interactive experiences, and its applications in healthcare are revolutionizing the sector in myriad ways. Mixed Reality Defined Mixed Reality is a fusion of both Augmented Reality (AR) and Virtual Reality (VR). While AR overlays digital information onto the real world, VR immerses users entirely into a computer-generated environment. MR, on the other hand, seamlessly blends these two experiences, allowing users to interact with virtual objects w...
Read more

Leuprolide Acetate Market Share, Analysis and Projection, Region - Global Forecast to 2030

Market Scenario The leuprolide acetate market size is projected to reach USD 2,400 Million by 2030 at 10.50% CAGR during the forecast period 2022-2030. Leuprolide acetate is a medication used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, and early puberty . The medication works by decreasing testosterone levels in men and estrogen levels in women . The report states that the increasing prevalence of prostate cancer and endometriosis is expected to drive the growth of the leuprolide acetate market in the projected timeframe . The report also highlights that side effects such as hot flashes, night sweats, decreased libido, erectile dysfunction, and osteoporosis associated with leuprolide acetate treatment are some factors which will likely act as market restraints for the growth of the leuprolide acetate market in the above mentioned projected timeframe . Key Players: GPI Golrang pharmaceutical investment (Russia), Bachem(Switzerland), avenit AG (...
Read more

Insulin Biosimilars Market Report, Key Trends, Competitive Scenario, Current and Future Players 2032

Insulin Biosimilars Market Highlights A disease in which the body’s ability to produce or respond to the hormone insulin is impaired, resulting in abnormal metabolism of carbohydrates and elevated levels of glucose in the blood is termed diabetes. Biosimilar insulin is designed to be highly like the original, or reference, insulin product described in a patent. As patents for major branded insulin products start to expire, several biosimilar insulin markets are expected to launch in the coming years. According to MRFR analysis, Insulin Biosimilars Market size is expected to reach USD 1.68 billion by 2032 at a CAGR of 14.6% during the forecast period of 2023 to 2032. The USFDA approved new insulin glargine Basilar, for type 1 and type 2 diabetes which is a biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim’s biosimilar insulin glargine has got approval through the European Medicines Agency’s (EMA’s) Biosimilar p...
Read more